Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma

OBJECTIVE: O6methylguanine-DNA methyltransferase (MGMT) promoter methylation is a biomarker widely used to predict the sensitivity of IDH-wildtype glioblastoma to temozolomide therapy. Given that the IDH status has critical effects on the survival and epigenetic features of glioblastoma, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Ruichao, Li, Guanzhang, Liu, Yuqing, Zhang, Kenan, Zhao, Zheng, Wu, Fan, Chang, Yuzhou, Pang, Bo, Li, Jingjun, Li, Yangfang, Jiang, Tao, Wang, Yongzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877176/
https://www.ncbi.nlm.nih.gov/pubmed/33628600
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877176/
https://www.ncbi.nlm.nih.gov/pubmed/33628600
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0179

Ejemplares similares